financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Keeps Strong Sell Opinion On Shares Of Cintas Corporation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Keeps Strong Sell Opinion On Shares Of Cintas Corporation
May 1, 2024 6:29 AM

09:05 AM EDT, 05/01/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target to $620 from $550, 38.4x our FY 25 (May) EPS outlook (adjusted to $16.15 from $16.37; we lift FY 24's estimate to $14.90 from $14.65), above the company's five-year forward P/E multiple average. A beat on earnings and raised guidance is driving today's positive movement in share price. CTAS posted Feb-Q EPS of $3.84 vs. $3.18 (+22% Y/Y), $0.26 above consensus. Feb-Q sales were roughly in line with expectations, up 10% Y/Y (an increase of 8% on an organic basis). Margin performance drove earnings expansion during the quarter, with operating income margin widening by 120 bps to 21.6%. Profitability benefited from volume growth, technology improvements, and gains from investment into operational efficiencies. Investment into route optimization and plant equipment utilization are bearing fruit. Despite the solid quarter and our positive view of CTAS's execution on margins and sales expansion, we view valuation as extended, with a forward P/E of 40x at nearly double that of the S&P 500.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
May 8, 2024
Treating America's obesity epidemic is turning into big business. Two pharmaceutical companies, Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) , are leading the weight-loss revolution with a new class of drugs known as GLP-1 agonists. Surging revenue and growing excitement has led some analysts to compare the success of GLP-1 drugs in the health and wellness...
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Trade Desk, Inc.
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Trade Desk, Inc.
May 8, 2024
12:45 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target at $100, on a P/E of 53.5x our '25 view, above peers but within its 10-year historical forward average. We keep our above consensus '24...
Research Alert: CFRA Lowers Opinion On Shares Of United Parks & Resorts Inc. To Hold From Buy
Research Alert: CFRA Lowers Opinion On Shares Of United Parks & Resorts Inc. To Hold From Buy
May 8, 2024
02:35 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target to $56 from $61, on 2024 EV/EBITDA of 7.3x, near the low-end of PRKS's long-term trading range of 7x-12x. We lift our 2024 EPS to...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings Plc
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings Plc
May 9, 2024
08:05 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We adjust our 12-month target to $120 from $140, on a lower revised peer-premium P/E of 64.8x our CY 25 EPS estimate, warranted given our view of growth prospects. We...
Copyright 2023-2026 - www.financetom.com All Rights Reserved